Abstracts tagged "Measurement Instrument"

Abstract Number: 2609 • ACR Convergence 2025
Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study
Nam Nguyen¹, Mu Yang², Sibel Aydin³, Gurjit Kaeley⁴, Richard Cook² and Lihi Eder¹, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, Canada, ³Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Psoriatic arthritis (PsA) is often diagnosed late, leading to worse outcomes. Enthesitis is a key feature that can aid in early detection, but its…
Abstract Number: 0605 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
Anubhav Singh¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Zoila Rodriguez-Bellido⁴, Cesar Pastor-Asurza⁵, Risto Perich-Campos⁶, Manuel Ugarte-Gil⁷ and Graciela Alarcón⁸, ¹Baptist hospital of southeast Texas, Beaumont, TX, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷Universidad Cientifica del Sur, Lima, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) was developed to ascertain frailty in systemic lupus erythematosus (SLE) patients. The aim of this…
Abstract Number: 2554 • ACR Convergence 2025
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Didem Saygin¹, Elizabeth Neal², Edward O'Bryan³, Alisha Smith, PharmD³, Leslie Myers³ and Timothy Walton³, ¹Rush University Medical Center, Chicago, IL, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Nash
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are autoimmune diseases typically characterized by muscle weakness. Intravenous Immunoglobulin (IVIg) is an effective immunomodulatory therapy in patients with refractory…
Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Leila Khalili¹, Cynthia Aranow², Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Alberto Nordmann-Gomes⁶, Maya Souvignier⁶, Wei Tang⁷, Stephen Suh⁸, Maria Dall'Era⁹, Meghan mackay¹⁰ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medical University of South Carolina, Johns Island, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Columbia University Irving Medical Center, New York, NY, ⁷Westchester Medical Center, Valhalla, NY, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Division of Rheumatology, University of California, San Francisco, CA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…
Abstract Number: 2542 • ACR Convergence 2025
A Rule Based NLP Pipeline for Glucocorticoid exposure
Simran Nimal¹, Megan Sullivan¹, Christopher Conyers², Joseph Rosen¹, Christopher Grilli¹, Kenneth Warrington³ and Victor E Ortega¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Scottsdale-⁸⁵²⁵⁹, AZ, ³Mayo Clinic, ROCHESTER, MN
Background/Purpose: Glucocorticoids (GCs) are essential for managing giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), but prolonged use poses risk due to cumulative dosing and…
Abstract Number: 0777 • ACR Convergence 2025
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Kevin Byram¹, Herman Mann², Danielle Hammond³, Sinisa Savic⁴, Yohei Kirino⁵, Carmelo Gurnari⁶, Mael Heiblig⁷, Thibault Comont⁸, Arsène Mekinian⁹, Mrinal Patnaik¹⁰, Lachelle D. Weeks¹¹, Gary Ho¹², Onima Chowdhury¹³, Adam Al-Hakim¹⁴, Scott Goldberg¹⁵, Marcela ferrada¹⁶, Sophie georgin-Lavialle¹⁷, Peter Grayson¹⁸, Emma Groarke¹⁹, Bhavisha Patel²⁰, Megan Sullivan²¹, Sarah A. Buckley²², Bryan G. harder²², Sandra Goble²², Matthew Koster¹⁰ and David Beck²³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Institute of Rheumatology, Praha ², Czech Republic, ³The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁷Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁸Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁹Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Dana Farber Cancer Institute, Boston, MA, ¹²New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ¹³Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ¹⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, ¹⁵New York University Grossman School of Medicine, Brooklyn, NY, ¹⁶University of Maryland, Bethesda, MD, ¹⁷Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ²⁰National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ²¹Mayo Clinic Arizona, Scottsdale, AZ, ²²Sobi Inc., Waltham, MA, ²³Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY
Background/Purpose: VEXAS syndrome is a recently described severe disease characterized by a complex overlap of inflammatory and hematologic features. Due to the severity and refractory…
Abstract Number: 2483 • ACR Convergence 2025
Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Gulsen Ozen¹, Lan Yu², Maureen Lauffoon², John Pauling³ and Robyn Domsic², ¹University of Iowa Carver College of Medicine, Coralville, IA, ²University of Pittsburgh, Pittsburgh, PA, ³North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Raynaud’s phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc) leading to substantial pain and impaired hand function. Establishing treatment efficacy for…
Abstract Number: 0449 • ACR Convergence 2025
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Joel Kremer¹, Kevin Kane², George Reed³ and Michael Weinblatt⁴, ¹The Corrona Research Foundation, Delray Beach, FL, ²U of Mass Medical School, Worcester, MA, MA, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…
Abstract Number: 2318 • ACR Convergence 2025
Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
Khalid Alnaqbi¹, Mohammed Alaswad², Tariq Al Araimi³, Amr Mahmoud⁴, Samar Al emadi⁵, Hanan Al Rayyes⁶, Khuloud Mohammed⁷ and Xenofon Barliakos⁸, ¹Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, ²Faculty of Human Medicine, University of Hama, Hama, Syria, ³Royal Hospital, Muscat, Oman, ⁴Department of Pharmacology, Pharmacy Program, Oman College of Health Sciences, Muscat, Oman, ⁵Hamad medical corporation, Doha, Qatar, ⁶Department of Medicine, Prince Sultan Military Medical City, Riyad, Saudi Arabia, ⁷Farwaniya Hospital, Kuwait, Kuwait, ⁸Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: There is a dearth of literature exploring challenges faced by rheumatologists in the referral, diagnosis, management, and monitoring of patients with suspected axial spondyloarthritis…
Abstract Number: 0386 • ACR Convergence 2025
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: The West Haven-Yale Multidimensional Pain Inventory (MPI) is a validated tool designed to assess the multidimensional aspects of chronic pain, including the 5 dimensions…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…
Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Grant Cannon¹, Beth Wallace², Deana Lazaro³, Pascale Schwab⁴, Paul Monach⁵, Ankoor Shah⁶, Gail Kerr⁷, Andreas Reimold⁸, Joshua Baker⁹, Gary Kunkel¹⁰, Katherine Wysham¹¹, Liron Caplan¹², John Richards¹³, Aleksander Lenert¹⁴, Andrew Jones¹⁵, Ted Mikuls¹⁶, Maria I. ("Maio") Danila¹⁷, Bryant England¹⁶, Brian Sauer¹⁸, Jorge Rojas¹⁹ and Isaac Smith²⁰, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³VA New York Harbor Healthcare system, Short Hills, NJ, ⁴VA Portland and Oregon Health & Science University, Portland, OR, ⁵VA Boston Healthcare System, Boston, MA, ⁶Duke University, Durham, NC, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²Rocky Mountain Regional VAMC, Aurora, CO, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴University of Iowa, Iowa City, IA, ¹⁵VA Saint Louis and Washington University, Saint Louis, ¹⁶University of Nebraska Medical Center, Omaha, NE, ¹⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁹VA Puget Sound Health Care System, Seattle, WA, ²⁰Duke University Hospital, Durham, NC
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…
Abstract Number: 2301 • ACR Convergence 2025
Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Sara M. Stern¹, Angela Merritt², Ludovic Trinquart³, Emma Barnboym⁴, Michelle LeeBravatti³, Suzy Richins⁵, Tressie L. Rollins⁵, Hanna M. Salzman⁵, Marisha Palm³, Cortney M. Wieber⁶, Hermine Brunner⁷ and Nora G. Singer⁸, ¹University of Utah, Salt Lake City, UT, ²Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ³Tufts University School of Medicine, Boston, MA, ⁴The MetroHealth System at Case Western Reserve University School of Medcine, Cleveland, OH, ⁵Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁶Institute for Clinical Research and Health Policy Studies (ICRHPS) and CTSI, Tufts School of Medicine, Boston, MA, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Childhood Sjogren Disease (cSjD) is a rare disease that presents with a wide variety of symptoms. Compared to adult SjD, cSjD more frequently manifests…
Abstract Number: 2171 • ACR Convergence 2025
Knowledge of Fertility and Infertility Treatments Among Physicians Treating Women with Rheumatic Diseases: FIT-KS Survey
Andres M. Ortiz-Rios¹, Mara Alejandra Ponce-Santillan¹, Braulio R. Avalos-Garcia¹, Eva Abigaid Galindo-Calvillo¹, Carolina Treviño-Sanchez¹, Samantha Lynn Salinas-Rodriguez¹, Arantza Michelle Núñez-Elizondo², Erendira Berenice Noyola-Sauceda¹, Guadalupe Valentina Vazquez-Guerra¹, Jesus Alberto Cardenas-de la Garza³, Lorena Perez-Barbosa¹, Dionicio A. Galarza-Delgado⁴ and Cassandra Michele Skinner-Taylor¹, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Rheumatic diseases frequently affect individuals of reproductive age, and up to 40–70% may experience fertility issues related to disease activity, medications, delayed childbearing, and…
Abstract Number: 1990 • ACR Convergence 2025
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Alex Tinianow¹, Saiajay Chigurupati¹, Ethan Carey¹, Jiaqi Wang², Sharan Rai³, Gregory Challener⁴, Hyon K. Choi⁵, Philip Riches⁶, Natalie McCormick¹ and Chio Yokose⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴MGH, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶NHS Lothian, Edinburgh, UK, Edinburgh, United Kingdom, ⁷Massachusetts General Hospital, Waltham, MA
Background/Purpose: Rheumatology guidelines endorse a treat-to-target (TTT) approach targeting serum urate (SU) < 6 mg/dL among patients with gout who qualify for urate-lowering therapy (ULT).…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].